Compare OI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | PRCT |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | OI | PRCT |
|---|---|---|
| Price | $16.45 | $27.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $17.43 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,455,000,000.00 | $299,907,000.00 |
| Revenue This Year | $1.39 | $48.30 |
| Revenue Next Year | $1.43 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.07 |
| 52 Week Low | $9.23 | $27.23 |
| 52 Week High | $16.69 | $75.29 |
| Indicator | OI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 32.26 |
| Support Level | $14.91 | $28.76 |
| Resistance Level | $16.69 | $29.94 |
| Average True Range (ATR) | 0.45 | 1.46 |
| MACD | 0.09 | -0.23 |
| Stochastic Oscillator | 92.93 | 0.00 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.